Despite China Weakness, Lilly Gung-Ho On Forteo, Humalog
This article was originally published in PharmAsia News
Eli Lilly said in its Q4 earning call that slowdown in emerging markets would continue in the coming year, highlighting a tough year in China, with possible worse growth in the country depending on its on-going whole pricing policies. Though some brands will remain strong and accelerate growth, particularly Forteo.
Register for our free email digests: